Phenibut

Overview

Phenibut (β-phenyl-GABA) is a non-peptide small-molecule GABA analogue that acts primarily as a GABA-B receptor agonist, with weaker GABA-A activity and secondary binding to the α2-δ subunit of voltage-dependent calcium channels. Developed and approved in Russia/former Soviet states since the 1960s for anxiety, sleep disturbance, and related conditions, it is not FDA-approved and is not a lawful dietary ingredient in the United States; FDA has issued warning letters to supplement marketers. Phenibut is widely documented in case literature for dependence, severe withdrawal syndromes (including delirium and seizures), and is sold in a gray market as an unregulated nootropic despite regulatory action.

Mechanism of Action

Phenibut is a structural GABA analogue that acts primarily as a GABA-B receptor agonist, with affinity (~92 μM for R-phenibut) markedly weaker than baclofen (~6 μM), and secondary activity at GABA-A receptors. The R-enantiomer also binds the α2-δ subunit of voltage-dependent calcium channels (Ki ~23 μM) and exerts gabapentin-like anti-nociceptive effects in rodent models. Additional proposed mechanisms include stimulation of dopamine receptors and antagonism of β-phenethylamine, though these are less well characterized than the GABA-B action.

Research Summary

No registered interventional clinical trials were found on ClinicalTrials.gov (API totalCount=0). Phenibut was developed and used clinically in Russia beginning in the 1960s for anxiety, sleep disturbance, peri-operative sedation, asthenia, PTSD, stuttering, and vestibular disorders, reflecting legacy regulatory approval abroad rather than FDA-reviewed randomized controlled trial data. Human data otherwise consists of case reports and case series documenting toxicity, dependence, and withdrawal rather than controlled efficacy trials. Rodent studies showed decreased neuronal activation in hippocampus and neocortex, increased neuronal synchronization, and reduced behavioral reactivity/anxiety; rat brain membrane binding studies confirmed R-phenibut binding to the α2-δ subunit of voltage-dependent calcium channels and gabapentin-like anti-nociceptive effects in rodent pain models.

Reported Side Effects

• Dependence and severe withdrawal (anxiety, agitation, insomnia, tremor, palpitations, nausea/vomiting)
• Delirium, hallucinations, and seizures in severe withdrawal cases
• Not FDA-approved; FDA has issued warning letters to supplement marketers
• 73% of case-series patients had history of alcohol/drug abuse; 60% had anxiety/depression history
• Rapid CNS penetration with ~5.3-hour half-life (case-report data)

Compare Phenibut with Others

Research References

• Phenibut (β‐Phenyl‐GABA): A Tranquilizer and Nootropic Drug. 2001. PMID 11830761.
• R-phenibut binds to the α2-δ subunit of voltage-dependent calcium channels and exerts gabapentin-like anti-nociceptive effects. 2015. PMID 26234470.
• Phenibut: A drug with one too many "buts". 2024.
• A Systematic Review of Phenibut Withdrawals.

Frequently asked questions

Has Phenibut been independently lab-tested?

Disclosed Labs has collected 6 Certificates of Analysis (COA) for Phenibut from 4 independent testing labs. 1 vendor has submitted material for testing. Products average 99.9% tested purity across the corpus. Full testing data is available at https://www.disclosedlabs.com/peptides/phenibut/testing.

What is the average purity of Phenibut on the market?

Based on 6 COAs analyzed by Disclosed Labs, Phenibut products average 99.9% (±0.1%) tested purity. Individual vendor results vary; see per-vendor COA data at https://www.disclosedlabs.com/peptides/phenibut/coas.

How does Phenibut work?

Phenibut is a structural GABA analogue that acts primarily as a GABA-B receptor agonist, with affinity (~92 μM for R-phenibut) markedly weaker than baclofen (~6 μM), and secondary activity at GABA-A receptors. The R-enantiomer also binds the α2-δ subunit of voltage-dependent calcium channels (Ki ~23 μM) and exerts gabapentin-like anti-nociceptive effects in rodent models. Additional proposed mechanisms include stimulation of dopamine receptors and antagonism of β-phenethylamine, though these are less well characterized than the GABA-B action.

What does the research say about Phenibut?

No registered interventional clinical trials were found on ClinicalTrials.gov (API totalCount=0). Phenibut was developed and used clinically in Russia beginning in the 1960s for anxiety, sleep disturbance, peri-operative sedation, asthenia, PTSD, stuttering, and vestibular disorders, reflecting legacy regulatory approval abroad rather than FDA-reviewed randomized controlled trial data. Human data otherwise consists of case reports and case series documenting toxicity, dependence, and withdrawal rather than controlled efficacy trials. Rodent studies showed decreased neuronal activation in hippocampus and neocortex, increased neuronal synchronization, and reduced behavioral reactivity/anxiety; rat brain membrane binding studies confirmed R-phenibut binding to the α2-δ subunit of voltage-dependent calcium channels and gabapentin-like anti-nociceptive effects in rodent pain models.